BACKGROUND: Concomitant radiotherapy and chemotherapy with @entity136 appears to be a promising tool for the treatment of @entity788 since @entity136 -- applied as single or combination therapy -- proved to have better efficacy in @entity788 than @entity1487 containing schemes and furthermore offers radiosensitizing potential. In the present paper our pilot data of concomitant and sequential chemoradiation with @entity136 and @entity900 are presented. @entity1 AND METHODS: A total of 57 @entity1 (f/m 23/34) with @entity788 was treated, of whom 33 @entity1 had irresectable @entity5 , 19 @entity1 following resection (R1 and/or pN+) and five @entity1 with @entity13177 . Radiotherapy was delivered in 25 fractions up to a total dose of 45.0 Gy specified according to ICRU reference point (50 @entity1 , 1.8 Gy/fraction) respectively 50.0 Gy to gross @entity5 volume (seven @entity1 ; 45.0 Gy in locoregional lymphatic pathways; 2.0/1.8 Gy/fraction). Concomitant with radiotherapy @entity900 (30 mg/m(2)) and @entity136 (300 mg/m(2)) were applied on days 1, 8, 22 and 29. After simultaneous chemoradiation two sequential cycles @entity136 and @entity900 (1000 mg/m(2) and 50 mg/m(2) d 1, 15) were applied. RESULTS: With a median follow-up of 8.2 months the median survival time was 14.8 months (irresectable @entity1 : 10.3 months, postoperative @entity1 , 15.1 months). Within 33 irresectable @entity1 19 and four partial and complete remissions, respectively, were observed. In 14 @entity1 a secondary resection was possible. Using leveled antiemetics with @entity3974 and @entity619 no gastrointestinal @entity137 grade III or IV were observed. Hematologic @entity137 were the most grave side effects ( @entity1431 III/IV in 29/five @entity1 and @entity882 III/IV in 21/eight @entity1 ), however with minor clinical relevancy (one @entity281 , one @entity1415 ). CONCLUSION: The presented treatment scheme using concomitant and sequential @entity136 and @entity900 with radiation is feasible with justifiable side effects. To evaluate the promising remission and survival rates, randomized trials of neoadjuvant and primary chemoradiation are started.

[Radiochemotherapy with XXXX and @entity900 in @entity788 -- feasible and effective].

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity3974 :: ('MESH:D017294', 'Chemical') :: ['ondansetron'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity13177 :: ('MESH:D009364', 'Disease') :: ['local recurrent disease'] @entity1415 :: ('MESH:D004844', 'Disease') :: ['thrombopenic epistaxis'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity281 :: ('MESH:D007239', 'Disease') :: ['neutropenic infection'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukocytopenia'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU']
@entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']
